Investigational drug · Phase 3
Favezelimab
Also called: MK-4280, MK-4820A
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Carcinoma, Renal Cell, Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
2 still active
All registered trials
18
Any phase or sponsor naming "Favezelimab"
First trial start
2018
Aug 21, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Favezelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Carcinoma, Renal Cell
- Solid Tumors
- Hematologic Malignancies
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Solid Tumor
- Cutaneous Squamous Cell Carcinoma
- Endometrial Cancer
- Hodgkin Lymphoma
Approved drugs for the same conditions: Melanoma · Bladder and urothelial cancer · Endometrial cancer · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Favezelimab" as an intervention, largest first.
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02720068 · 481 participants · Start May 2, 2016 · Primary completion Mar 15, 2024
Drug: Favezelimab; Pembrolizumab and 6 more · For: Neoplasms
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05064059 · 441 participants · Start Nov 10, 2021 · Primary completion Aug 15, 2024
Drug: favezelimab/pembrolizumab; regorafenib and 1 more · For: Colorectal Cancer
Sites: Washington D.C., District of Columbia; Marietta, Georgia; Louisville, Kentucky · 152 sites in all
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05845814 · 390 participants (planned) · Start Jun 23, 2023 · Primary completion May 31, 2027
Drug: Coformulated favezelimab/pembrolizumab; Coformulated vibostolimab/pembrolizumab and 1 more · For: Metastatic Urothelial Carcinoma; Urothelial Neoplasms
Sites: La Jolla, California; Orange, California; San Francisco, California · 47 sites in all
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04305054 · 335 participants · Start Jul 1, 2020 · Primary completion May 18, 2026
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 60 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04895722 · 302 participants · Start Jun 25, 2021 · Primary completion May 21, 2025
Drug: Pembrolizumab; Pembrolizumab/Quavonlimab and 3 more · For: Colorectal Cancer
Sites: Orange City, Florida; Athens, Georgia; Chicago, Illinois · 109 sites in all
- Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02625961 · 296 participants · Start Feb 10, 2016 · Primary completion Nov 5, 2025
Drug: Pembrolizumab; Pembrolizumab/vibostolimab coformulation and 1 more · For: Bladder Cancer
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03516981 · 245 participants · Start Oct 1, 2018 · Primary completion Jun 13, 2025
Drug: Pembrolizumab; Favezelimab and 2 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Tempe, Arizona; Sacramento, California; San Francisco, California · 81 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.
Timmerman J, Lavie D, Johnson NA, et al. · Blood Neoplasia 2026
- Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.
Johnson NA, Lavie D, Borchmann P, et al. · Blood Adv 2026
- Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.
Gaurav M, Barcomb H, Maxwell KF, et al. · Clin Transl Sci 2026
- Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
Suarez C, Rojas C, Shin SJ, et al. · Ann Oncol 2026
- Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma.
Armand P, Zinzani PL, Timmerman J, et al. · Blood Adv 2025
- Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
Martínez-Pérez A, Granda-Díaz R, Aguilar-García C, et al. · Biomark Res 2024
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.